Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure-Reference-Cited by-同舟云学术

Role of Liver Transplantation in Tolvaptan-Associated Acute Liver Failure

Published:2019-11 Issue:11 Volume:4 Page:1653-1657
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Endo Mayumi,Katayama Kan^ORCID,Matsuo Hiroshi,Horiike Shinichiro,Nomura Shinsuke,Hayashi Akinobu,Ishikawa Eiji,Harada Tetsuro,Sugimoto Ryosuke,Tanemura Akihiro,Sugimoto Kazushi,Isaji Shuji,Ito Masaaki

Publisher

Elsevier BV

Subject

Nephrology

Reference8 articles.

1. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference;Chapman;Kidney Int,2015

2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials;Miyazaki;Cardiovasc Drug Rev,2007

3. Tolvaptan in patients with autosomal dominant polycystic kidney disease;Torres;N Engl J Med,2012

4. Evidence-based clinical practice guidelines for polycystic kidney disease 2014;Horie;Clin Exp Nephrol,2016

5. Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial;Muto;Drug Healthc Patient Saf,2017

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Effects of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Predictors of Treatment Response and Safety over 6 Years of Continuous Therapy;International Journal of Molecular Sciences;2024-02-08

2. Otomozal dominant polikistik böbrek hastalığında tolvaptan kullanımı: Tek merkez deneyimi;Anadolu Kliniği Tıp Bilimleri Dergisi;2023-09-28

3. Renal ciliopathies: promising drug targets and prospects for clinical trials;Expert Opinion on Therapeutic Targets;2023-05-04

4. Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease;The Korean Journal of Internal Medicine;2023-05-01

5. Pharmacologic Management of Autosomal Dominant Polycystic Kidney Disease;Advances in Kidney Disease and Health;2023-05